HCPCS code J2506: Pegfilgrastim injection, per 0.5 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J2506 covers

J2506 represents non-biosimilar pegfilgrastim, a long-acting granulocyte colony-stimulating factor used to reduce the risk of infection associated with chemotherapy-related neutropenia. It is commonly given by subcutaneous injection after myelosuppressive cancer treatment. Oncology practices and hospital outpatient departments may report the drug when they furnish it; the code represents the medication, not the injection service. Neulasta is a familiar reference product for non-biosimilar pegfilgrastim.

CMS assigns physician fee schedule status E, excluding this drug from the physician fee schedule. When Medicare covers it, payment is through another method; the HCPCS pricing designation identifies it as a Part B drug generally priced from CMS quarterly ASP drug files. Coverage is left to the Medicare contractor’s judgment. One billing unit represents 0.5 mg, or 500 mcg, of pegfilgrastim. Report units based on the amount administered and retain documentation supporting the product and dose. Biosimilar pegfilgrastim products are reported with their applicable biosimilar codes, not J2506.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J2506 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J2506 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J2506 rate is calculated

Each of J2506’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J2506

J2506 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J2506 compared with similar codes

How to choose

Q5108Fulphila injectionPer 0.5 mg

Use Q5108 for pegfilgrastim-bmez, a biosimilar product. J2506 is for pegfilgrastim excluding biosimilars.

Q5111Udenyca injectionPer 0.5 mg

Use Q5111 for pegfilgrastim-cbqv, a biosimilar product; use J2506 for non-biosimilar pegfilgrastim.

J1442Filgrastim injectionPer 1 microgram

J1442 is filgrastim, a different G-CSF drug, reported per 1 mcg. J2506 is pegfilgrastim reported per 0.5 mg.

Codes related to J2506

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates